A new purification strategy for fraction 1 capsular antigen and its efficacy against Yersinia pestis virulent strain challenge

被引：25

作者：

Wang, Tang ^{[1
]}

Qi, Zhizhen ^{[2
]}

Wu, Benchuan ^{[3
]}

Zhu, Ziwen ^{[1
]}

Yang, Yonghai ^{[2
]}

Cui, Baizhong ^{[2
]}

Dai, Ruixia ^{[2
]}

Zhang, Qingwen ^{[2
]}

Qiu, Yefeng ^{[1
]}

Wang, Zuyun ^{[2
]}

Wang, Hu ^{[2
]}

Guo, Zhaobiao ^{[1
]}

Wang, Xiaoyi ^{[1
]}

Yang, Ruifu ^{[1
]}

机构：

[1] Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Lab Analyt Microbiol, Beijing 100071, Peoples R China

[2] Qinghai Inst Endem Dis Prevent & Control Qinghai, Xining 811602, Peoples R China

[3] Beijing Inst Bioengn, Beijing 100071, Peoples R China

来源：

PROTEIN EXPRESSION AND PURIFICATION | 2008年 / 61卷 / 01期

基金：

国家高技术研究发展计划(863计划);

关键词：

Yersinia pestis; F1; antigen; purification; protection;

D O I：

10.1016/j.pep.2008.05.003

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

F1 antigen is an attractive candidate for the development of a subunit vaccine against plague. In previous study, the extraction of this antigen from Yersinia pestis is characterized by using organic solvents. In this work, a new purification strategy that produced high-purity F1 antigen from Y. pestis EV76 was developed by the substitution of physical disruption for organic solvent one, followed by a combination of ammonium sulfate fractionation and Sephacryl S-200HR column filtration chromatography. As revealed in this study, this purification procedure is simple and effective, and avoids potential adverse effect on the antigen by organic solvents. Highly purified F1 that adsorbed to 25% (v/v) Al(OH)(3) adjuvant in phosphate-buffered saline (PBS) induced very high titers of antibody to F1 in BALB/c mice and protected them (100% survival) against subcutaneous challenge with 10(4) CFU of Y. pestis virulent strain 141. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：7 / 12

页数：6

共 17 条

[1] Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge [J].

Andrews, GP ;

Heath, DG ;

Anderson, GW ;

Welkos, SL ;

Friedlander, AM .

INFECTION AND IMMUNITY, 1996, 64 (06) :2180-2187

[2] Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis [J].

Du, YD ;

Rosqvist, R ;

Forsberg, Å .

INFECTION AND IMMUNITY, 2002, 70 (03) :1453-1460

[3] Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine [J].

Heath, DG ;

Anderson, GW ;

Mauro, JM ;

Welkos, SL ;

Andrews, GP ;

Adamovicz, J ;

Friedlander, AM .

VACCINE, 1998, 16 (11-12) :1131-1137

[4] CAF1-R GENE AND ITS ROLE IN THE REGULATION OF CAPSULE FORMATION OF Y-PESTIS [J].

KARLYSHEV, AV ;

GALYOV, EE ;

ABRAMOV, VM ;

ZAVYALOV, VP .

FEBS LETTERS, 1992, 305 (01) :37-40

[5] A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice [J].

Morton, M ;

Garmory , HS ;

Perkins, SD ;

O'Dowd, AM ;

Griffin, KF ;

Turner, AK ;

Bennett, AM ;

Titball, RW .

VACCINE, 2004, 22 (20) :2524-2532

[6]

Perrow C., 1997, Organization Environment, V10, P66, DOI [https://doi.org/10.1177/0921810697101009, DOI 10.1177/0921810697101009]

[7] Turning Yersinia pathogenesis outside in:: subversion of macrophage function by intracellular yersiniae [J].

Pujol, U ;

Bliska, JB .

CLINICAL IMMUNOLOGY, 2005, 114 (03) :216-226

[8] Field evaluation of an immunoglobulin G anti-F1 enzyme-linked immunosorbent assay for serodiagnosis of human plague in Madagascar [J].

Rasoamanana, B ;

Leroy, F ;

Boisier, P ;

Rasolomaharo, M ;

Buchy, P ;

Carniel, E ;

Chanteau, S .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (05) :587-591

[9]

Riedel Stefan, 2005, Proc (Bayl Univ Med Cent), V18, P116

[10] A COMPARISON OF PLAGUE VACCINE, USP AND EV76 VACCINE-INDUCED PROTECTION AGAINST YERSINIA-PESTIS IN A MURINE MODEL [J].

RUSSELL, P ;

ELEY, SM ;

HIBBS, SE ;

MANCHEE, RJ ;

STAGG, AJ ;

TITBALL, RW .

VACCINE, 1995, 13 (16) :1551-1556

← 1 2 →